doi: 10.1161/hc4801.100236
(Circulation. 2001;104:2778.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
Double-Blind, Randomized Trial of an Anti-CD18 Antibody in Conjunction With Recombinant Tissue Plasminogen Activator for Acute Myocardial Infarction
Limitation of Myocardial Infarction Following Thrombolysis in Acute Myocardial Infarction (LIMIT AMI) Study
From John Nasseff Heart Hospital, St Paul, Minn (K.W.B.); Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada (M.N.); Rhode Island Hospital, Providence, RI (G.R.M.); Maine Medical Center, Portland, Maine (C.T.L.); Jane Phillips Medical Center, Bartlesville, Okla (G.D.); Robert Wood Johnson University Hospital, New Brunswick, NJ (S.T.P.); Mayo Clinic, Rochester, Minn (R.J.G.); Henry Ford Health System, Detroit, Mich (S.B.); University of Vermont, Burlington, Vt (B.E.S.); Genentech, Inc, South San Francisco, Calif (S.G.G., A.C.R., H.V.B.); and the University of California at San Francisco (S.G.G., C.M.G., H.V.B.).
Correspondence to Kenneth W. Baran, MD, St Paul Heart Clinic, 255 North Smith Avenue, St Paul, MN 55102. E-mail kbaran{at}stphc.com
Background— Inhibition of leukocyte adhesion can reduce myocardial infarct size in animals. This study was designed to define the safety and efficacy of a recombinant, humanized, monoclonal antibody to the CD18 subunit of the ß2 integrin adhesion receptors (rhuMAb CD18), in reducing infarct size in patients treated with a thrombolytic agent.
Methods and Results— The Limitation of Myocardial Infarction following Thrombolysis in Acute Myocardial Infarction Study (LIMIT AMI) was a randomized, double-blind, placebo-controlled, multicenter study conducted in 60 centers in the United States and Canada. A total of 394 subjects who presented within 12 hours of symptom onset with ECG findings (ST-segment elevation) consistent with AMI were treated with recombinant tissue plasminogen activator and were also given an intravenous bolus of 0.5 or 2.0 mg/kg rhuMAb CD18 or placebo. Coronary angiography was performed at 90 minutes, 12-lead ECGs were obtained at baseline, 90, and 180 minutes, and resting sestamibi scans were performed at 
120 hours. Adjunctive angioplasty and use of glycoprotein IIb/IIIa antiplatelet agents at the time of angiography were discretionary. There were no treatment effects on coronary blood flow, infarct size, or the rate of ECG ST-segment elevation resolution, despite the expected induction of peripheral leukocytosis. A slight trend toward an increase in bacterial infections was observed with rhuMAb CD18 (P=0.33).
Conclusions— RhuMAb CD18 was well tolerated but not effective in modifying cardiac end points.
Key Words: myocardial infarction • cell adhesion molecules • inflammation • antibodies • trials
This article has been cited by other articles:
 |
|
 |
|
  A. Merched, K. Tollefson, and L. Chan {beta}2 integrins modulate the initiation and progression of atherosclerosis in low-density lipoprotein receptor knockout mice Cardiovasc Res, November 21, 2009; (2009) cvp347v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Stone Angioplasty Strategies in ST-Segment-Elevation Myocardial Infarction: Part II: Intervention After Fibrinolytic Therapy, Integrated Treatment Recommendations, and Future Directions Circulation, July 29, 2008; 118(5): 552 - 566. [Full Text] [PDF]
|
|
|
|
|
|
D. Fujioka, Y. Saito, T. Kobayashi, T. Yano, H. Tezuka, Y. Ishimoto, N. Suzuki, Y. Yokota, T. Nakamura, J.-e. Obata, et al. Reduction in Myocardial Ischemia/Reperfusion Injury in Group X Secretory Phospholipase A2-Deficient Mice Circulation, June 10, 2008; 117(23): 2977 - 2985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kasama, M. Furuya, T. Toyama, S. Ichikawa, and M. Kurabayashi Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction Eur. Heart J., June 2, 2008; 29(12): 1485 - 1494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bujak, H. J. Kweon, K. Chatila, N. Li, G. Taffet, and N. G. Frangogiannis Aging-Related Defects Are Associated With Adverse Cardiac Remodeling in a Mouse Model of Reperfused Myocardial Infarction J. Am. Coll. Cardiol., April 8, 2008; 51(14): 1384 - 1392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Schneider, Y. Zhu, T. Coleman, and C. F. Semenkovich Macrophage 3 Integrin Suppresses Hyperlipidemia-Induced Inflammation by Modulating TNF{alpha} Expression Arterioscler Thromb Vasc Biol, December 1, 2007; 27(12): 2699 - 2706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Seo and J. M. Hare The Transforming Growth Factor-{beta}/Smad3 Pathway: Coming of Age as a Key Participant in Cardiac Remodeling Circulation, November 6, 2007; 116(19): 2096 - 2098. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Orr, J. M. Taylor, S. Cartland, P. G. Bannon, C. Geczy, and L. Kritharides Conformational activation of CD11b without shedding of L-selectin on circulating human neutrophils J. Leukoc. Biol., November 1, 2007; 82(5): 1115 - 1125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Yellon and D. J. Hausenloy Myocardial Reperfusion Injury N. Engl. J. Med., September 13, 2007; 357(11): 1121 - 1135. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Schramm, M. D. Menger, S. Kirsch, F. Langer, Y. Harder, J. Hamacher, and H.-J. Schafers The subepicardial microcirculation in heterotopically transplanted mouse hearts: An intravital multifluorescence microscopy study J. Thorac. Cardiovasc. Surg., July 1, 2007; 134(1): 210 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Dirksen, G. J. Laarman, M. L. Simoons, and D. J.G.M. Duncker Reperfusion injury in humans: A review of clinical trials on reperfusion injury inhibitory strategies Cardiovasc Res, June 1, 2007; 74(3): 343 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The APEX AMI Investigators Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial JAMA, January 3, 2007; 297(1): 43 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. J. Gibson and C. M. Gibson The association of impaired myocardial perfusion and monocytosis with late recovery of left ventricular function following primary percutaneous coronary intervention Eur. Heart J., November 1, 2006; 27(21): 2487 - 2488. [Full Text] [PDF]
|
|
|
|
|
|
D. T. Mangano, Y. Miao, I. C. Tudor, C. Dietzel, for the Investigators of the Multicenter Study of, and and the Ischemia Research and Education Foundation Post-Reperfusion Myocardial Infarction: Long-Term Survival Improvement Using Adenosine Regulation With Acadesine J. Am. Coll. Cardiol., July 4, 2006; 48(1): 206 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fukushima, S. R. Coppen, A. Varela-Carver, K. Yamahara, P. Sarathchandra, R. T. Smolenski, M. H. Yacoub, and K. Suzuki A Novel Strategy for Myocardial Protection by Combined Antibody Therapy Inhibiting Both P-Selectin and Intercellular Adhesion Molecule-1 Via Retrograde Intracoronary Route Circulation, July 4, 2006; 114(1_suppl): I-251 - I-256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Vasilyev, T. Williams, M.-L. Brennan, S. Unzek, X. Zhou, J. W. Heinecke, D. R. Spitz, E. J. Topol, S. L. Hazen, and M. S. Penn Myeloperoxidase-Generated Oxidants Modulate Left Ventricular Remodeling but Not Infarct Size After Myocardial Infarction Circulation, November 1, 2005; 112(18): 2812 - 2820. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ferenc and F.-J. Neumann Efficacy of primary PCI: the microvessel perspective Eur. Heart J. Suppl., October 1, 2005; 7(suppl_I): I4 - I9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Libby and P. Theroux Pathophysiology of Coronary Artery Disease Circulation, June 28, 2005; 111(25): 3481 - 3488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Ross, R. J. Gibbons, G. W. Stone, R. A. Kloner, R. W. Alexander, and for the AMISTAD-II Investigators A Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II) J. Am. Coll. Cardiol., June 7, 2005; 45(11): 1775 - 1780. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D. Horne, J. L. Anderson, J. M. John, A. Weaver, T. L. Bair, K. R. Jensen, D. G. Renlund, J. B. Muhlestein, and Intermountain Heart Collaborative (IHC) Study Grou Which White Blood Cell Subtypes Predict Increased Cardiovascular Risk? J. Am. Coll. Cardiol., May 17, 2005; 45(10): 1638 - 1643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Morgan, L. Harper, X. Lu, G. Nash, J. Williams, and C. O. S. Savage Can neutrophils be manipulated in vivo? Rheumatology, May 1, 2005; 44(5): 597 - 601. [Full Text] [PDF]
|
|
|
|
|
|
K. Yonekawa and J. M. Harlan Targeting leukocyte integrins in human diseases J. Leukoc. Biol., February 1, 2005; 77(2): 129 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Barrabes, D. Garcia-Dorado, M. Mirabet, J. Inserte, L. Agullo, B. Soriano, A. Massaguer, F. Padilla, R.-M. Lidon, and J. Soler-Soler Antagonism of selectin function attenuates microvascular platelet deposition and platelet-mediated myocardial injury after transient ischemia J. Am. Coll. Cardiol., January 18, 2005; 45(2): 293 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Gibbons, U. S. Valeti, P. A. Araoz, and A. S. Jaffe The quantification of infarct size J. Am. Coll. Cardiol., October 19, 2004; 44(8): 1533 - 1542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Kloner and S. H. Rezkalla Cardiac protection during acute myocardial infarction: Where do we stand in 2004? J. Am. Coll. Cardiol., July 21, 2004; 44(2): 276 - 286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Vinten-Johansen Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury Cardiovasc Res, February 15, 2004; 61(3): 481 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Inagaki, L. Chen, F. Ikeno, F. H. Lee, K.-i. Imahashi, D. M. Bouley, M. Rezaee, P. G. Yock, E. Murphy, and D. Mochly-Rosen Inhibition of {delta}-Protein Kinase C Protects Against Reperfusion Injury of the Ischemic Heart In Vivo Circulation, November 11, 2003; 108(19): 2304 - 2307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. Mahaffey, C. B. Granger, J. C. Nicolau, W. Ruzyllo, W. D. Weaver, P. Theroux, J. S. Hochman, T. G. Filloon, C. F. Mojcik, T. G. Todaro, et al. Effect of Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Fibrinolysis in Acute Myocardial Infarction: The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) Trial Circulation, September 9, 2003; 108(10): 1176 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P.S. Henriques, F. Zijlstra, A. W.J. van 't Hof, M.-J. de Boer, J.-H. E. Dambrink, M. Gosselink, J. C.A. Hoorntje, and H. Suryapranata Angiographic Assessment of Reperfusion in Acute Myocardial Infarction by Myocardial Blush Grade Circulation, April 29, 2003; 107(16): 2115 - 2119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Sabatine, D. A. Morrow, C. P. Cannon, S. A. Murphy, L. A. Demopoulos, P. M. DiBattiste, C. H. McCabe, E. Braunwald, and C. M. Gibson Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: A TACTICS-TIMI 18 substudy J. Am. Coll. Cardiol., November 20, 2002; 40(10): 1761 - 1768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Faxon, R. J. Gibbons, N. A. F. Chronos, P. A. Gurbel, F. Sheehan, and HALT-MI Investigators The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study J. Am. Coll. Cardiol., October 2, 2002; 40(7): 1199 - 1204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. G. Angeja, M. Gunda, S. A. Murphy, B. E. Sobel, A. C. Rundle, M. Syed, A. Asfour, S. Borzak, S. G. Gourlay, H. V. Barron, et al. TIMI Myocardial Perfusion Grade and ST Segment Resolution: Association With Infarct Size as Assessed by Single Photon Emission Computed Tomography Imaging Circulation, January 22, 2002; 105(3): 282 - 285. [Abstract] [Full Text] [PDF]
|
|